82 results
Page 4 of 5
6-K
EX-99.3
409vt1c1z0115e7cg5j
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am
6-K
EX-99.1
29iao 17pr19g
16 Jan 20
CONTROLLING INFLAMMATION JP Morgan Corporate Presentation January 2020
4:11pm
6-K
EX-99.1
3xyjfcindg qq
14 Nov 19
Current report (foreign)
4:10pm
6-K
EX-99.4
neag2rv
7 Nov 19
Current report (foreign)
7:00am
6-K
EX-99.2
new 0e3on1i
7 Nov 19
Current report (foreign)
7:00am
6-K
EX-99.2
5e80s0f 3vc
14 Aug 19
Current report (foreign)
4:16pm
6-K
EX-99.1
9lpmruxq40yt6xaxjyft
18 Jul 19
InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa
4:12pm
6-K
EX-99.1
e20 aen0fzlyex8400w
5 Jun 19
Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa
7:12am
6-K
EX-99.2
4rbf26
23 May 19
Current report (foreign)
8:00am
6-K
EX-99.1
8bwcwnhy
8 May 19
IFX-1 C5a Controlling inflammation Corporate Presentation May 2019
6:02am
20-F/A
y6ja8 n0s228yq6l2jel
29 Mar 19
Annual report (foreign) (amended)
4:23pm
F-3ASR
m0j74
28 Mar 19
Automatic shelf registration (foreign)
9:09am
6-K
EX-99.1
qeclnnm9r acvv
6 Feb 19
InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa
8:35am
6-K
EX-99.2
i8fg6iol aj4jc7
21 Nov 18
Current report (foreign)
8:34am
6-K
EX-99.3
ibq00omfdcox
21 Nov 18
Current report (foreign)
8:34am
6-K
EX-99.1
vgzcr3 913c98
8 Nov 18
InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa
8:52am
6-K
EX-99.2
g6yy1zi
9 Aug 18
Current report (foreign)
7:35am
6-K
EX-99.2
456v5pzi8wu4qsr3c
17 May 18
Current report (foreign)
7:45am
424B4
w2ul1f8vn1jnb
7 May 18
Prospectus supplement with pricing info
4:47pm